HLX53 + serplulimab + bevacizumab

**HLX53 + serplulimab + bevacizumab** is an experimental combination regimen evaluated primarily for cancer therapy, especially in advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC) and hepatocellular carcinoma. - **Serplulimab** is a humanized monoclonal antibody that blocks programmed death-1 (PD-1), functioning as an immune checkpoint inhibitor (immunotherapy). - **Bevacizumab** (also referred to as HLX04, a biosimilar to Avastin) is a humanized monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis (formation of blood vessels that supply tumors). - **HLX53** is another investigational product that, in this specific combination, is currently being trialed, but detailed public data on its molecular target is limited; in typical studies with serplulimab and bevacizumab, HLX53 is under joint development by Henlius. This combination, especially serplulimab plus bevacizumab (HLX04), has been shown to have a manageable safety profile and promising anti-tumor activity in phase 2 studies for NSCLC with brain metastases and advanced hepatocellular carcinoma[1][3][5][7].

Brand names

HLX04HLX-04HLX 04

Other names

HLX53 + serplulimab + HLX04